-
06:28:59 PM

APLIF Stock News

03/20/23 7:18 AM
OTC : APLIF
Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement with Long Zone Holdings Inc., amending and restating the original secured loan agreement by and between Appili and LZH dated March 25, 2022.
RHEA-AI
neutral
02/14/23 7:18 AM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022. “Over the past couple of months, it has been an immense honor to serve as the company’ s CEO and I’ m...
RHEA-AI
neutral
01/17/23 7:12 AM
OTC : APLIF
management
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of...
RHEA-AI
neutral
01/13/23 7:19 AM
OTC : APLIF
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’ s liquid oral reformulation of the antibiotic metronidazole.
RHEA-AI
neutral
11/14/22 7:45 AM
OTC : APLIF
partnership
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency in partnership with the U.S. Air Force Academy, will provide at least US $14 million in funding over...
RHEA-AI
neutral
11/10/22 7:38 AM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022. “We continue to move significantly closer to being able to provide a safe and effective vaccine...
RHEA-AI
neutral
08/12/22 4:54 PM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022. “As threats from both known and emerging infectious diseases loom around the world, I’ m proud that Appili...
RHEA-AI
neutral